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Abstract: Israeli acute paralysis virus (IAPV), a single-stranded RNA virus, has a
worldwide distribution and affects honeybees as well as other important pollinators. IAPV
infection in honeybees has been successfully repressed by exploiting the RNA interference
(RNAi) pathway of the insect’s innate immune response with virus-specific double stranded
RNA (dsRNA). Here we investigated the effect of IAPV infection in the bumblebee Bombus
terrestris and its tissue tropism. B. terrestris is a common pollinator of wild flowers in Europe
and is used for biological pollination in agriculture. Infection experiments demonstrated a
similar pathology and tissue tropism in bumblebees as reported for honeybees. The effect
of oral administration of virus-specific dsRNA was examined and resulted in an effective
silencing of the virus, irrespective of the length. Interestingly, we observed that non-specific
dsRNA was also efficient against IAPV. However further study is needed to clarify the precise
mechanism behind this effect. Finally we believe that our data are indicative of the possibility
to use dsRNA for a broad range viral protection in bumblebees.
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1. Introduction
Managed bees are used worldwide as pollinators to aid food production in open field as well
as in greenhouses [1]. Honeybees and bumblebees are the two most commonly used species for
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commercial pollination purposes. Domesticated honeybees are hosts to multiple viruses [2–4], but
also different bumblebee species have been reported to carry viruses [5,6]. Managed bees could act
as reservoirs for pathogens, and spillover of pathogens from managed bees toward wild pollinators could
disrupt natural host-pathogen interactions [7]. Mainly for protozoan parasites from reared bumblebees
this phenomena has been studied [8–12], but also disturbance of host-pathogen interaction in wild
bumblebees by domesticated honeybees could be happening [6,13]. The risks associated with pathogen
spillover could in certain geographic regions be one of the drivers responsible for the decline of
pollinators [7,14]. Pathogen eradication in managed bees can already prevent initial spillover events.
For honeybees the administration of dsRNA has been successfully applied to lower infection levels
of several pathogens, for example Israeli acute paralysis virus (IAPV), Deformed wing virus (DWV),
Chinese sacbrood virus (CSBV) and Nosema ceranae [15–19]. For bumblebees oral administration
of dsRNA has remained unexplored, although genome analysis revealed the presence of the RNAi
pathway [20] responsible for processing dsRNA into short interfering RNA (siRNA). These siRNAs
target RNA with the corresponding sequence which leads to cleavage of the targeted RNA with the
help of Dicer-2. Indeed injection of gene-specific dsRNA can induce gene silencing in bumblebees [21]
and also IAPV-specific silencing was obtained after injection of virus-specific dsRNA [22]. This RNAi
mechanism has long been reasoned to be the main antiviral immune response in invertebrates as they
would lack a non-specific antiviral response. However more recent reports also suggest the presence of a
non-specific antiviral response in invertebrates triggered by nucleic acids, as dsRNA, that are recognized
as pathogen-associated molecular patterns (PAMPs) [23–25]. Still, more research is needed to clarify
the precise pathways of this response.
In contrast to honeybees, bumblebees are reared in a closed environment, therefore it should
be feasible to produce pathogen-free bumblebees via a combination of screening and preventative
measures [26]. dsRNA could help to achieve this goal. Although caution is needed, as in honeybees
treatment with dsRNA cannot eliminate the infections [15,17,18], it can significantly lower the viral
titer, and thereby perhaps reduce it to titers below the threshold for horizontal transmission. Another
option is the application of dsRNA as a preventive treatment. Here we hypothesize that treatment with
dsRNA, prior to infection, could prime the bumblebee, making virus infection less likely. This priming
could not only eliminate viral spread within breeding facilities, but could also immunize bumblebees
when they are used in the field. Indeed aside from the above discussed pathogen spillover mechanism,
spillback principles are often overlooked [27]. In spillback the introduced species, in our case a managed
bumblebee, could be picking up local parasites or viruses and act as a new host disturbing natural
host-pathogen interactions. Here we reported on how different dsRNA treatments can lower infection
with IAPV, a virus present in honeybees and bumblebees, causing damage in both species and possibly
other pollinators.
2. Materials and Methods
2.1. Viral Stock
For the production of the viral stock we obtained 240 adult bumblebees from virus-free colonies
(Biobest, Westerlo, Belgium). One hundred twenty bumblebees were injected with 2 µL of IAPV
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solution containing 200 virus particles. The starting virus solution originated from honeybees and
was kindly provided by Joachim de Miranda (Swedish University of Agricultural Sciences, Uppsala,
Sweden), and quantified by transmission electron microscopy (CODA-CERVA, Brussels, Belgium) as
described by Meeus et al. [28]. The other 120 bumblebees were injected with nuclease free water and
served as a control. After injection bumblebees were kept in micro-colonies of 10 workers at 30 ◦C
and 60% RH (MLR-352 incubator, Sanyo/Panasonic, Osaka, Japan) and ad libitum access to 50% sugar
water (Bioglucr, Biobest) [29]. Four days after injection the bumblebees were stored at −80 ◦C until
the virus purification. Bumblebees were crushed in 0.01 M phosphate buffer (pH 7.0) 0.02% diethyl
dithiocarbamate. The exoskeletons were discarded and the remaining liquid was centrifuged (20 min
800× g). Supernatant was collected and centrifuged at 40,000× g for 4 h at 4 ◦C. The pellet was
suspended in nuclease free water and stored at −80 ◦C. We performed a quality control on both the
viral stock and the control inoculum. Only the virus stock contained IAPV, checked with primers
described by Cox-Foster et al. [30]. The virus titer was checked with transmission electron microscopy
(CODA-CERVA) resulting in 1× 108 virus particles/µL. We screened for possible contaminating viruses
in both viral stock and control inoculum, we tested for slow bee paralysis virus, Kashmir bee virus, acute
bee paralysis virus and DWV with PCR and all were negative. Finally, the infectivity of the prepared
viral stock and control inoculum solution was tested by injection of 2 µL control inoculum and viral
stock. Four days after injection the infection status was determined with PCR [30]. The viral stock
solution could successfully infect, and no infection was detected when 2 µL of the control inoculum
was injected.
2.2. IAPV Infectivity and Mortality
Bumblebees of the same age were kept in micro-colonies per treatment, in an incubator (MLR-352,
Sanyo/Panasonic) at 30 ◦C, 60% RH and constant darkness. Bees had ad libitum access to 50% sugar
water (Bioglucr, Biobest, Westerlo, Belgium) [29]. Prior to feeding bumblebees were starved for 4 h.
Bumblebees were inoculated individually in separate boxes (Ø 9 cm) with water (n = 17), or with 1× 107
(n = 16), 2 × 107 (n = 16) and 1 × 108 (n = 18) virus particles in a 20 µL droplet of 50% sugar water
(Bioglucr, Biobest). Feeding was done under red light, to minimize disturbance of the bees. After
inoculation behavior and mortality were followed for 20 days. After 20 days, the infection status of the
bees was checked by PCR as described by Cox-Foster et al. [30]. Survival analysis was done in SPSS
Statistics (version 22.0, IBM Corp, Armonk, NY, USA) with the Mantel-Cox (log rank) test. At day
4 and day 7 post infection 2 bumblebees fed with either 1 × 107 or 1 × 108 were sacrificed for tissue
tropism analysis, these bumblebees were not included in the survival analysis.
2.3. dsRNA Administration and Effects on Infectivity and Mortality of IAPV Infected Bees
To test the effect of dsRNA on IAPV infectivity and mortality, we fed dsRNA on a daily basis for 6
consecutive days to bumblebees of the same age. Each day a 4h-starved bee received 2 µg of dsRNA in
20 µL of 50% sugar water (Bioglucr, Biobest). On the third day the bees also received 1 × 107 virus
particles suspended in 20 µL of 50% sugar water (Bioglucr, Biobest) [29]. Bees were fed individually
as described earlier. In the first experiment bees were put in micro-colonies per treatment after each
feeding session and behavior and mortality were scored for 22 days. In the second experiment bees were
Viruses 2015, 7 3175
kept individually during the whole course of the experiment. Five days after the last dsRNA feeding day
bumblebees were sacrificed and stored at −80 ◦C until extraction to determine the viral titer.
2.4. Extraction and Virus Quantification
The gut, fat body and head of the bumblebees was dissected and crushed in 350 µL RLT
buffer (supplied with the Qiagen RNeasy Mini kit). Further RNA extraction proceeded according
manufacturer’s protocol (RNeasy Mini Kit, Qiagen, Venlo, The Netherlands) and were stored at
−80 ◦C until further use. RNA concentrations and purity were determined using a NanoDrop ND-1000
spectrophotometer. A two-step real time RT-PCR was used for quantification of IAPV. First cDNA was
made (SuperScriptr II Reverse Transcriptase, Life Technologies, Carlsbad, CA, USA) using 500 ng
of RNA and oligo-dT primers, according to manufacturer’s protocol. The cDNA was 10 times diluted
and IAPV was quantified using a CFX96™ Real-Time PCR Detection system (Bio-Rad, Hercules, CA,
USA), performing each reaction in duplicate. The total reaction volume of 20 µL contained 10 µL
GoTaqr qPCR Master Mix, (Promega, Madison, WI, USA), 1 µL (10 µM) Forward and 1 µL (10 µM)
Reverse primer (see Table 1) and 8 µL diluted cDNA. Nuclease free water was used as a negative control
(NTC). Peptidylprolyl isomerase A (PPIA), reported as a stable reference gene in B. terrestris with IAPV
infection was used for normalization as described by Niu et al. [31]. The qPCR protocol for both IAPV
(E = 92.6%) and PPIA (E = 79.3%) reference gene was as follows: 95 ◦C for 5 min, 40 cycles of 95 ◦C
for 30 s and 60 ◦C for 1 min. The relative normalized IAPV titer was determined as the IAPV titer
after normalization with the reference gene PPIA. All qPCR data was processed with the Bio-Rad CFX
Manager 3.0 Software (Bio-Rad).
Table 1. Primers used for Israeli acute paralysis virus (IAPV) detection, for virus
quantification and for dsRNA synthesis, T7 promotor-sequence not included.
Target Use Forward Primer (5′→3′) Reverse Primer (5′→3′) Reference
IAPV PCR CGAACTTGGTGACTTGAAGG GCATCAGTCGTCTTCCAGGT [30]
PPIA RT-qPCR TCGTAATGGAGTTGAGGAGTGA CTTGGCACATGAAGTTTGGAAT [31]
IAPV RT-qPCR CCATGCCTGGCGATTCAC CTGAATAATACTGTGCGTATC [31]
dsVP586 dsRNA ACCTGGAAGACGATTGATGC CTGCCCACTTCCAAACAACT This study
dsVP443 dsRNA TATAGATGCCGCTCCATGTG CTGCCCACTTCCAAACAACT This study
dsVP293 dsRNA ACCTGGAAGACGATTGATGC GTGGGTTTGACGGGTATCAC This study
2.5. dsRNA Synthesis
The RNA extract from the IAPV stock solution was subjected to a DNase treatment and subsequently
to RT-PCR with oligo-dT primers, as described earlier. The fragments corresponding to the structural
protein-coding region, dsVP586 (bases 7986-8571; accession: NC_009025.1) were PCR amplified with
primers (Table 1) carrying a T7 promotor-sequence at the 5′ end, dsRNA for this target was synthesized
for three different lengths, 293 bp (dsVP293); 443 bp (dsVP443); and 586 bp (dsVP586). Primers were
designed using Primer3 software [32], dsRNA was further produced according manufacturer’s protocol
(MEGAscriptr RNA kit, Life Technologies), except in the elution step where nuclease free water was
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used to elute the dsRNA instead of elution buffer. Eluted dsRNA was subjected to a DNAse treatment.
dsRNA for GPF (dsGFP, 455 bp) was produced in the same way, starting from a plasmid containing the
nucleotide sequence for GFP. The sequences of all dsRNA fragments were compared to the genome of
B. terrestris and did not contain any similarity longer than 20 bp [20].
3. Results
3.1. Infectivity of IAPV in Bumblebees and Its Effect on Survival
Previous studies showed that 0.5 × 107 IAPV particles is near the minimum amount required for oral
infection in bumblebees, and reported no significant effect on mortality with this dose [28]. Here we
inoculated bumblebee workers with three different doses of IAPV (i.e., 1 × 107, 2 × 107 and 1 × 108)
and tested the infection status (n = 2, per dose per time point) in different body parts (i.e., head, gut and
fat body) after four and seven days. For all treatments we also followed mortality and bee behavior.
After a single oral administration of 1 × 108 virus particles, we were able to detect IAPV in the head,
gut and fat body both four and seven days post infection (p.i.). Feeding of 1 × 107 virus particles had
a slower infection progression as IAPV was only detectable in the gut at 4 days p.i., while it took until
day seven for virus to appear in the other tested body parts. This reduced infection progression was also
apparent in the survival scoring of the bumblebees. Figure 1 shows that feeding of 1 × 108 IAPV virus
particles resulted in significant increased mortality after 20 days (p = 0.001, Mantel-Cox) compared to the
no virus control. Feeding of 2 × 107 virus particles resulted in reduced survival, although not significant
(p = 0.09, Mantel-Cox). When 1× 107 virus particles were fed, there was nearly no increase in mortality,
which is consistent with previous reports showing only sub-lethal effects [28]. IAPV therefore seems
to have a similar pathology in bumblebees as in honeybees. Indeed high mortality within 10 days after
feeding of IAPV was reported for honeybees [33]. Experiments comparing doses in honeybees and
bumblebees and the naturally occurring titers of IAPV are needed to draw further conclusions.
Looking at the behavior of the bumblebees we noticed disorientated movements: the bumblebees
moved around lifting their paws high in the air and tipping over frequently. These observations were not
recorded before, and were only seen when high amounts (1 × 108 or 2 × 107) of virus particles were
fed and shortly before dying. In honeybees infected with IAPV similar symptoms of spasms have been
reported shortly before dying [33]. Darkening of the abdomen is described for IAPV infected honeybees
as an early symptom [33], while in bumblebees no such symptoms were recorded in our experiments.
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days before and three days after inoculation could not prevent infection. After eight days all tested 
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In Figure 2b, the relative IAPV titers of both the dsVP586 and dsGFP treatment are compared at  
eight days p.i. in different body parts. We detected a markedly lower relative normalized virus titer in 
the head (p < 0.001), the gut (p = 0.015) and the fat body (p = 0.014) in the dsGFP-treated samples 
compared to the dsVP586 treatment. This result was somewhat unexpected, but actually the impact of 
non-specific dsRNA (i.e., dsGFP) and the IAPV-specific dsRNA (i.e., dsVP586) on mortality followed 
the same pattern. The dsGFP control had a significantly higher survival compared to the virus-specific 
treatment (Mantel-Cox, p = 0.009) (Figure 2a). The dsGFP control showed a survival of 60% after  
22 days compared to only 10% survival for the dsVP586 treatment. Due to the design of the 
experiment, where we wanted to test if virus-specific dsRNA could prevent infection, dsGFP served as 
a control and no virus-only control was used, as infection success with no treatment was proven in the 
first experiment. Therefore we cannot draw conclusions on the silencing efficiency, however the 
observed effect of dsGFP compared to the virus-specific dsRNA treatment remains noteworthy. This 
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sRNA on the infection success. Administration of dsVP586 (n = 10) and dsGFP (n = 10) three days
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(i.e., head, gut and fat body) (n = 5, each treatment) were infected.
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non-specific dsRNA (i.e., dsGFP) and the IAPV-specific dsRNA (i.e., dsVP586) on mortality followed
the same pattern. The dsGFP control had a significantly higher su vival compared to the virus-specific
treatment (Mantel-Cox, p = 0. 09) (Figure 2a). The dsGFP control showed a survival of 60% after
22 days compar d to only 10% survival for the dsVP586 treatment. Du to the d sign of the exp riment,
where we wanted to test if virus-specific dsRNA could prevent infection, dsGFP served as a control and
no virus-only control was used, as infection success with no treatment was proven in the first experiment.
Therefore we cannot draw conclusions on the silencing efficiency, however the observed effect of
dsGFP compared to the virus-specific dsRNA treatment remains noteworthy. This effect contradicts
with previous studies on the use of dsRNA on IAPV infected honeybees, where the non-specific dsRNA
control, also dsGFP, had no effect on the survival compared to the virus-specific dsRNA [15]. For DWV
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infected adult honeybees a slight positive effect of dsGFP on the survival was reported, although the
specific dsRNA was significantly better than the dsGFP treatment [18]. Feeding of dsRNA specific for
CSBV could prevent infection in larvae as opposed to the unrelated dsGFP, for which there was also no
effect on survival [17].
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first experiment. Figure 3 gives the relative virus titer in the head of a virus-only control (oral inoculation
of IAPV and later on sugar water instead of dsRNA), dsGFP administration as well as all three different
IAPV-specific dsRNA treatments. Here all virus-specific treatments showed a significant drop in virus
titers compared to the virus-only control (p < 0.05). The length of the dsRNA molecule did not have
a significant effect on the virus silencing with the IAPV-specific fragment, as there was no significant
difference in virus titer between all three virus-specific fragments (p > 0.10). The viral titer of the dsGFP
control was significantly different from the only-virus control (p < 0.05) but not from the virus-specific
treatments (p > 0.10). These findings confirm the positive effect of dsGFP found in the first experiment.
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taken, as we provide the first evidence of the impact of IAPV on single workers, the impact on queens
and colony development is still missing. Indeed wild nest are very hard to find, but studying the impact
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on colony level is also of importance as wild bees often go through more harsh conditions compared
to honeybees [38]. The biological relevance of feeding such high doses of virus particles to look at
pathology remains to be tested for IAPV. On the other hand, viral loads as high as 1 × 109 RNA copies
have been detected in bee feces for chronic bee paralysis virus (CBPV) [39], giving some idea about
biological relevant doses that can be a source for infection. IAPV has also been detected in honeybee
feces although there are no quantitative data so far [37]. Indeed fecal-oral transmission is suggested as
one of the main transmission routes between taxa [9,40]. This can happen through shared flower use
where feces could contaminate the exterior of the bee and thereafter the nectar as well as the pollen of
flowers [5]. The impact of IAPV on wild bees needs further investigation as we provide initial evidence
that this virus may also be detrimental to bumblebees as is reported for honeybees [41,42].
4.2. dsRNA As Possible Treatment to Prevent Spillback Principles
The risk of pathogen spillover associated with the use of commercial bumblebees is well
described [8,40,43,44]. However, the use of pathogen free commercial bees can also disturb the natural
host-pathogen equilibrium, as these bees can be competent hosts for the native pathogens and so increase
the pathogen prevalence, the so called spillback mechanism [27,45]. Here we investigated if oral
administration of dsRNA could be of help to prevent IAPV infection in bumblebees, this in an effort
to prevent spillback of viruses in pathogen free managed bees. In honeybees this technique successfully
lowered the viral titer and prolonged the lifespan of infected bees [15–18]. Administration of dsRNA
was not able to prevent infection with IAPV in bumblebees. Feeding of dsRNA could significantly
prolong the lifespan of the infected bumblebees and significantly lower the virus titer. It therefore seems
that initial infection of naturally occurring viruses will not be prevented, but the reduced viral replication
holds promising results. Indeed dsRNA treatment of managed bees could in this way prevent massive
infection loads of these bees, avoiding spillback of viruses into the environment. If these lower virus
titers will indeed diminish the possibility of spreading infectious doses of virus and prevent spillback
mechanisms needs to be further investigated.
4.3. Does Non-Specific dsRNA Works as A PAMP in Bumblebees?
The effect of IAPV-specific dsRNA molecules on the virus titer suggests the presence of a functional
specific antiviral RNAi immune response in bumblebees, as all the genes required for the RNAi
machinery are present in the genome of B. terrestris [20].
Our results, done in bumblebees, demonstrate that a non-specific dsRNA molecule has the same
or even higher potency to silence IAPV. In honeybees, virus-specific dsRNA proofed to be more
effective to silence viruses compared to non-specific dsRNA [15,17,18]. This suggests that the role
of a virus-unspecific immune response might be of greater importance in bumblebees. It remains
speculative if the massive domestication and long term selection towards high honey productive
honeybees had its trade-offs toward diminished efficiency of certain innate viral immune pathways.
On the other hand no effect of inbreeding was observed for encapsulation and phenoloxidase activity,
in honeybees [46]. However, the impact of inbreeding and selection on viral immune responses in
honeybees still remains unexplored.
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The effect of non-specific dsRNA molecules on virus titer and survival has been reported in several
invertebrates including honeybees [23,24], thus a pronounced presence in bumblebee is possible.
Actually the amount of evidence supporting the hypothesis that there is also a non-specific antiviral
response in invertebrates triggered by nucleic acid molecules, as dsRNA, is rising [23]. Flenniken
and Andino [24] persued an attempt to find the immune pathways involved in the virus silencing by
non-specific dsRNA. Microarray analysis and qPCR in honeybees after virus infection or administration
of non-specific dsRNA, diminishing viral loads, revealed that most up-regulated genes could not be
linked with previously reported immune pathways. They suggested the involvement of uncharacterized
signal transduction cascades in virus control by non-specific dsRNA [24]. Although it could be
that known pathways are still involved but regulation is missed by microarray and qPCR, as these
techniques are limited to see regulation on mRNA level. While these techniques miss post-transcriptional
regulation like post-translational modification. Furthermore, it could also be that the precise time point
of up-regulation of the involved cascade genes was missed, further study is needed to clarify this.
Although the exact immune response pathway is unknown, it seems that non-specific dsRNA acts as a
PAMP triggering the anti-viral defense. It could be that PAMP recognition strengthens the conventional
RNAi pathway, making it more efficient when the actual virus infects and triggers the virus-specific
RNAi machinery. But it could also be that in bumblebees other viral defense pathways like the
JAK-STAT, Imd, Toll or Jun-N-terminal kinase immune pathways are more or equally important and
triggered by non-specific dsRNA molecular patterns.
Feeding experiments in honeybees, all show a clear effect of virus-specific dsRNAs [15,16,18];
injection experiments with Sindbis virus in honeybees on the other hand demonstrated an effect of
non-specific dsRNA [24] similar to our results in bumblebees after feeding. We can speculate that the
siRNA response in different host and against different viruses is not clear-cut. Aside from the influence
of the host and virus on antiviral responses it seems the method of delivery can also have an influence.
We hypothesize that the biological importance of a certain immune pathway, be it the siRNA pathway
(triggered by virus-specific dsRNA) or other pathways, even for the same virus within the same host
can be different, depending on the mode of infection and severity of the infection. Furthermore also
the actual fitness of the host, its immunologic competence, and genetic background are at play. This
would explain the differences reported between non-specific dsRNA and virus-specific dsRNA in viral
silencing efficiency [15,17,18,24,25], as well as the differences observed in our experiments. In both
our experiments there was a positive effect of the non-specific dsRNA on the virus titer. In the first
experiment this effect was significantly higher compared to the virus-specific dsRNA treatment, however
in the second experiment there was no significant difference in the effect between the virus-specific and
non-specific dsRNA. As both experiments were conducted at different times, the bumblebees used for the
experiments originated from different colonies. During the course of both experiments the environmental
conditions were kept constant. However, the genetic and physiological background of the bees could be
different. It is known that both food stress [47] and genotype [48,49] can influence the innate immune
response of bumblebee workers.
Aside from which pathways is triggered, the fact that non-specific dsRNA can silence IAPV opens
avenues to prevent replication of multiple viruses in bumblebees. However, the effect of random dsRNA
on other viruses in bumblebees first need to be tested. Although our preventive treatment did not
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lower the infection success of 1 × 107 virus particles, it could significantly lower the virus titer. This
treatment could possibly protect bumblebees from high infections when placed in a natural environment
and prevent possible spillback.
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